Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement

Imunon, Inc.

2026-Q1 EPS reported -$0.84 vs consensus -$1.13 ▲ beat (+25.8%)

Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.
Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.
With PARP inhibitor maintenance, median OS 65.6 vs 41.4 months (+24.2 months) for IMNN-001 arm.
Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on BLA path.
Strategic reorganization in Feb 2026 reduced operating expenses; R&D expenses up to $2.3M from $2.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Imunon, Inc. reported the three months ended March 31, 2026 results: net income $4.3 million, EPS $0.84 per share.

Period: the three months ended March 31, 2026
Net income: $4.3 million
EPS: $0.84 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2026 was $4.3 million, or $0.84 per share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022401

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.